Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Altria's Q3 earnings beat estimates, but shares fell on a weak outlook and persistent category challenges, including declining cigarette volumes and e-vapor headwinds.
Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Altria's Q3 earnings beat estimates, but shares fell on a weak outlook and persistent category challenges, including declining cigarette volumes and e-vapor headwinds.